{"id":829,"date":"2025-07-11T06:43:03","date_gmt":"2025-07-11T06:43:03","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/829\/"},"modified":"2025-07-11T06:43:03","modified_gmt":"2025-07-11T06:43:03","slug":"geneticure-inc-granted-new-u-s-patent-for-genetic-test-to-predict-response-in-renal-denervation-for-hypertension","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/829\/","title":{"rendered":"Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension"},"content":{"rendered":"

\nThe patent supports the Company\u2019s broader mission to eliminate trial-and-error in treating hypertension (High Blood Pressure) with medications and medical devices.<\/p>\n

<\/a>
<\/a><\/p>\n

ROCHESTER, Minn.–(BUSINESS WIRE)–Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure\u2019s proprietary method of using a patient\u2019s genetic profile to predict their likelihood of benefiting from renal denervation \u2014 a minimally invasive procedure used to treat hypertension.<\/p>\n

\n\u201cRenal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other\u2019s experiencing no change or an increase in blood pressure post-denervation.\u201d said Scott Snyder, CEO of Geneticure. \u201cPrior to Geneticure\u2019s research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage.\u201d<\/p>\n

\nThe patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments.<\/p>\n

\nThis newly issued patent expands Geneticure\u2019s growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalized hypertension management.<\/p>\n

\nMore on Geneticure for Renal Denervation:<\/p>\n

\nhttps:\/\/www.slideshare.net\/slideshow\/genetic-scoring-related-to-renal-denervation-response\/254331538<\/a><\/p>\n

\nhttps:\/\/geneticure.com\/rdn\/<\/a><\/p>\n

\nAbout Geneticure<\/p>\n

\nGeneticure Inc. is an Integrated Computational Genomic medicine company focused on eliminating the trial-and-error approach to treating chronic diseases. By integrating a patient’s genetic information with physiologic insights, Geneticure provides physicians with actionable tools to optimize therapy selection and improve outcomes. The company\u2019s flagship offerings include genetic tests that predict response to common hypertension medications and now, response to renal denervation.<\/p>\n

Contacts <\/p>\n

\nMedia Contact:
Scott Snyder
\n
Chief Executive Officer
\n
Geneticure Inc.
\n
info@geneticure.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The patent supports the Company\u2019s broader mission to eliminate trial-and-error in treating hypertension (High Blood Pressure) with medications…\n","protected":false},"author":2,"featured_media":830,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-829","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=829"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/829\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/830"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}